medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 3

<< Back

Ann Hepatol 2016; 15 (3)

Bile acids and the risk for hepatocellular carcinoma in primary biliary cholangitis

Altamirano-Barrera A, Uribe M, Lammert F, Méndez-Sánchez N

Language: English
References: 12
Page: 453-454
PDF size: 107.88 Kb.


Text Extraction

Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the third most common cause of cancer death, and accounts for 5.6% of all cancers. Nearly 82% of the approximately 550,000 liver cancer deaths each year occur in Asia. In some regions, cancer-related death from HCC is second only to lung cancer.


REFERENCES

  1. Méndez-Sánchez N, Ridruejo E, Alves de Mattos A, Chávez-Tapia NC, Zapata R, Paraná R, Mastai R, et al. Latin American Association for the Study of the Liver (LAASL) Clinical Practice Guidelines: management of hepatocellular carcinoma. Ann Hepatol 2014; 13(Suppl. 1): S4-S40.

  2. Lammers WJ, Kowdley KV, van Buuren HR. Predicting outcome in primary biliary cirrhosis. Ann Hepatol 2014;13:316-26.

  3. Imam MH, Silveira MG, Sinakos E, Gossard AA, Jorgensen R, Keach J, DeCook AC, et al. Long-term outcomes of patients with primary biliary cirrhosis and hepatocellular carcinoma. Clin Gastroenterol Hepatol 2012; 10: 182-5.

  4. Trivedi PJ, Lammers WJ, van Buuren HR, Parés A, Floreani A, Janssen HL, Invernizzi P, et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut 2016; 65: 321-9.

  5. Liang Y, Yang Z, Zhong R. Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis. Hepatology 2012; 56: 1409: 17-27.

  6. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317: 121-4.

  7. Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet 2015; 386 (10003): 1565-75.

  8. Beuers U. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 318-28.

  9. Xiang X, Backman JT, Neuvonen PJ, Niemi M. Gender, but not CYP7A1 or SLCO1B1 polymorphism, affects the fasting plasma concentrations of bile acids in human beings. Basic Clin Pharmacol Toxicol 2012; 110: 245-52.

  10. Bennion LJ, Drobny E, Knowler WC, Ginsberg RL, Garnick MB, Adler RD, Duane WC. Sex differences in the size of bile acid pools. Metabolism 1978; 27: 961-9.

  11. Dilger K, Hohenester S, Winkler-Budenhofer U, Bastiaansen BA, Schaap FG, Rust C, Beuers U. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. J Hepatol 2012; 57: 133-40.

  12. Fiorucci S, Distrutti E, Ricci P, Giuliano V, Donini A, Baldelli F. Targeting FXR in cholestasis: hype or hope. Expert Opin Ther Targets 2014; 18: 1449-59.




2020     |     www.medigraphic.com